Blerp – Lifestyle
Author:
Classover Holdings Inc.
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
Classover Announces Full Year 2025 Financial Results: Gross Margin Expands, Makes Strategic Advances in AI and Robotics
April 2, 2026
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
April 1, 2026
Classover Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 31, 2026
Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
March 30, 2026
Classover Announces Strategic Robotics Education Collaboration with Walimaker to Expand AI and Robotics Learning Programs
March 13, 2026
Classover Announces Reverse Stock Split
March 5, 2026
←
Previous Page
1
2